Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiragolumab plus Atezolizumab in PD-L1-positive cervical cancer
NCT04300647Phase 2Completed
- Sponsor
- Roche
- Start
- Jun 2020
- Primary completion
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 17
01
Overview
A Phase 2 trial of tiragolumab in Cervical Cancer (CC), sponsored by Roche. Started Jun 2020; status: completed.
02
Drugs
tiragolumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04300647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04300647.